IDiyas

For the Inventor, By the Inventor

Birmingham, United Kingdom

Gurdyal S Besra

USPTO Granted Patents = 11 

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 48(Granted Patents)


Location History:

  • Solihull, GB (2013 - 2014)
  • West Midlands, GB (2015 - 2016)
  • Birmingham, GB (2011 - 2020)

Company Filing History:

goldMedal7 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal5 out of 118 
 
The University of Birmingham
 patents
bronzeMedal3 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
4. 2 out of 446 
 
Oxford University Innovation Limited
 patents
5. 1 out of 53 
 
Statens Serum Institut
 patents
where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...
11 patents (USPTO):Explore Patents
1. 10765648 - iNKT cell modulators and methods of using the same (2020-09-08),
2. 10314796 - iNKT cell modulators and methods of using the same (2019-06-11),
3. 9700532 - iNKT cell modulators and methods of using the same (2017-07-11),
4. 9517243 - Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2016-12-13),
5. 9365496 - iNKT cell modulators and methods of using the same (2016-06-14),
6. 9168291 - β-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2015-10-27),
7. 8835613 - β-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2014-09-16),
8. 8563009 - Use of monomycolyl glycerol (MMG) as an adjuvant (2013-10-22),
9. 8334408 - Analogs of alpha galactosylceramide and uses thereof (2012-12-18),
10. 8188313 - Analogs of alpha galactosylceramide and uses thereof (2012-05-29),
11. 8039670 - Analogs of alpha galactosyceramide and uses thereof (2011-10-18),

Title: Gurdyal S Besra: Innovator in iNKT Cell Modulation

Introduction

Gurdyal S Besra is a prominent inventor based in Birmingham, GB. He has made significant contributions to the field of immunology, particularly in the development of iNKT cell modulators. With a total of 11 patents to his name, Besra's work has the potential to impact various therapeutic approaches.

Latest Patents

Among his latest patents, Besra has disclosed innovative methods involving α-galactosylceramide (α-GalCer) analogs. These compositions are designed to activate invariant Natural Killer T (iNKT) cells. His patents detail methods for treating diseases by utilizing these analogs and explore combination therapies that enhance their effectiveness.

Career Highlights

Gurdyal S Besra has worked with notable institutions such as the Ludwig Institute for Cancer Research Limited and the University of Birmingham. His research has focused on advancing our understanding of immune responses and developing novel therapeutic strategies.

Collaborations

Some of his notable coworkers include Vincenzo Cerundolo and Liam R Cox. Their collaborative efforts have contributed to the advancement of research in the field of immunology.

Conclusion

Gurdyal S Besra's innovative work in iNKT cell modulation showcases his dedication to advancing medical science. His contributions through patents and collaborations highlight the importance of research in developing new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…